BRPI9810519B1 - derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. - Google Patents

derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.

Info

Publication number
BRPI9810519B1
BRPI9810519B1 BRPI9810519-1A BRPI9810519A BRPI9810519B1 BR PI9810519 B1 BRPI9810519 B1 BR PI9810519B1 BR PI9810519 A BRPI9810519 A BR PI9810519A BR PI9810519 B1 BRPI9810519 B1 BR PI9810519B1
Authority
BR
Brazil
Prior art keywords
homoerythromycin
deoxo
aza
derivatives
substituted
Prior art date
Application number
BRPI9810519-1A
Other languages
English (en)
Inventor
Brian Scott Bronk
Michael Anthony Letavic
Takushi Kaneko
Bingwei Vera Yang
Edward Alan Glazer
Hengmiao Cheng
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21959336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9810519(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI9810519A publication Critical patent/BRPI9810519A/pt
Publication of BRPI9810519B1 publication Critical patent/BRPI9810519B1/pt
Publication of BRPI9810519B8 publication Critical patent/BRPI9810519B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI9810519A 1997-06-11 1998-05-29 derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. BRPI9810519B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4934897P 1997-06-11 1997-06-11
PCT/IB1998/000839 WO1998056802A1 (en) 1997-06-11 1998-05-29 4'-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives

Publications (3)

Publication Number Publication Date
BRPI9810519A BRPI9810519A (pt) 2000-09-19
BRPI9810519B1 true BRPI9810519B1 (pt) 2012-02-22
BRPI9810519B8 BRPI9810519B8 (pt) 2022-11-16

Family

ID=21959336

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9810519A BRPI9810519B8 (pt) 1997-06-11 1998-05-29 derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.

Country Status (49)

Country Link
US (4) US6420536B1 (pt)
EP (1) EP0988310B9 (pt)
JP (2) JP3315704B2 (pt)
KR (1) KR100396168B1 (pt)
CN (4) CN1243766C (pt)
AP (1) AP1231A (pt)
AR (1) AR013086A1 (pt)
AT (1) ATE251173T1 (pt)
AU (1) AU749816B2 (pt)
BG (1) BG64391B1 (pt)
BR (1) BRPI9810519B8 (pt)
CA (1) CA2293823C (pt)
CO (1) CO4950611A1 (pt)
CZ (1) CZ298556B6 (pt)
DE (2) DE122004000018I2 (pt)
DK (1) DK0988310T3 (pt)
DZ (1) DZ2514A1 (pt)
EA (1) EA002441B1 (pt)
EG (1) EG24081A (pt)
ES (1) ES2205487T3 (pt)
FR (1) FR04C0013I2 (pt)
GT (1) GT199800077A (pt)
HN (1) HN1998000086A (pt)
HR (1) HRP980314B1 (pt)
HU (2) HU228005B1 (pt)
ID (1) ID22992A (pt)
IL (1) IL132809A0 (pt)
IS (1) IS1998B (pt)
LU (1) LU91076I9 (pt)
MA (1) MA24564A1 (pt)
ME (1) ME00876B (pt)
MY (1) MY123354A (pt)
NL (1) NL300150I2 (pt)
NO (1) NO316911B1 (pt)
NZ (2) NZ500660A (pt)
OA (1) OA11224A (pt)
PA (1) PA8452201A1 (pt)
PE (1) PE79699A1 (pt)
PL (1) PL191601B1 (pt)
PT (1) PT988310E (pt)
RS (1) RS49675B (pt)
SI (1) SI0988310T1 (pt)
SK (1) SK284171B9 (pt)
TN (1) TNSN98082A1 (pt)
TW (1) TW472060B (pt)
UA (1) UA67744C2 (pt)
UY (1) UY25040A1 (pt)
WO (1) WO1998056802A1 (pt)
ZA (1) ZA985017B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
ATE353014T1 (de) * 1997-09-10 2007-02-15 Merial Ltd Verwendung von 9a-azaliden als antimikrobielle mittel für tiere
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
EP1779853A3 (en) * 1997-09-10 2010-01-27 Merial Ltd. 9a-azalides as veterinary antimicrobial agents
AP9801420A0 (en) * 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
US6043227A (en) * 1998-08-19 2000-03-28 Pfizer Inc. C11 carbamates of macrolide antibacterials
EP1437360A3 (en) * 1998-08-19 2005-04-06 Pfizer Products Inc. C11 Carbamates of macrolide antibacterials
US6100240A (en) * 1998-10-09 2000-08-08 Pfizer Inc Macrolide derivatives
CA2292359C (en) * 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
EP1189912B1 (en) * 1999-05-18 2008-04-16 Pfizer Products Inc. Novel crystalline forms of a macrolide antibiotic
IL145739A0 (en) * 1999-05-24 2002-07-25 Pfizer Prod Inc 13-methyl-erythromycin derivatives
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
ATE315042T1 (de) * 1999-08-24 2006-02-15 Abbott Lab 9a-azalide mit antibakterieller wirkung
US6764996B1 (en) 1999-08-24 2004-07-20 Abbott Laboratories 9a-azalides with antibacterial activity
US6608033B1 (en) * 1999-08-27 2003-08-19 Pfizer Inc. Treatment or prevention of coccidiosis
BRPI0017013B1 (pt) 2000-01-27 2015-07-14 Zoetis P Llc Composição de antibiótico azalídeo e método para sua obtenção
AU4269301A (en) * 2000-04-27 2001-11-07 Pfizer Products Inc. The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals
WO2002088158A1 (en) * 2001-04-27 2002-11-07 Pfizer Products Inc. Process for preparing 4'-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
WO2003011266A2 (en) * 2001-08-01 2003-02-13 Pfizer Products Inc. Azalide antibiotic compositions
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
WO2005030227A1 (en) 2003-09-23 2005-04-07 Enanta Pharmaceuticals, Inc. 9a, 11-3C-BICYCLIC 9a-AZALIDE DERIVATIVES
CN1882360A (zh) * 2003-11-21 2006-12-20 辉瑞产品公司 抗生素作为疫苗佐剂的用途
EP2360165A3 (de) * 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US7402568B2 (en) 2004-09-29 2008-07-22 Enanta Pharmaceuticals, Inc. Bicyclic 9a-azalide derivatives
US7767797B1 (en) * 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
US7271155B2 (en) 2005-01-07 2007-09-18 Enanta Pharmaceuticals, Inc. 9A, 11-2C-bicyclic 9a-azalide derivatives
US20080227730A1 (en) * 2005-01-14 2008-09-18 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9A-Carbamoyl and Thiocarbamoyl Azalides With Antimalarial Activity
CA2703475A1 (en) * 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US8796232B2 (en) * 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) * 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (ja) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ,インコーポレイテッド マラリア、結核、及びmac病の治療方法
CN103080122A (zh) 2010-03-22 2013-05-01 森普拉制药公司 大环内脂的结晶形式及其用途
WO2011146829A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
JP6042334B2 (ja) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ,インコーポレイテッド 疾患治療のための水素結合形成フルオロケトライド
ES2532455T3 (es) * 2010-09-20 2015-03-27 Novartis Tiergesundheit Ag Nuevo procedimiento de preparación de 9-desoxo-9a-aza-9a-homoeritromicina modificada en el C-4'' del anillo de cladinosa por un grupo epóxido
CA2814333A1 (en) * 2010-10-10 2012-04-19 Synovo Gmbh Anti-inflammatory macrolides
CN102993250B (zh) * 2011-07-06 2016-02-10 洛阳惠中兽药有限公司 C-3取代的-9-脱氧-9a-氮杂-9a-高红霉素a衍生物
CN102260306B (zh) * 2011-07-22 2012-07-18 山东鲁抗舍里乐药业有限公司 一种制备泰拉霉素的方法
WO2013013834A1 (en) 2011-07-27 2013-01-31 Farma Grs, D.O.O. New crystalline forms of tulathromycin
CN104470527B (zh) 2012-03-27 2019-05-28 森普拉制药公司 用于施用大环内酯抗生素的肠胃外制剂
CN102786569B (zh) * 2012-09-07 2016-12-07 安徽中升药业有限公司 泰拉霉素中间体及其制备方法与泰拉霉素的制备方法
RU2015138796A (ru) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
WO2014145210A1 (en) 2013-03-15 2014-09-18 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
SI3027634T1 (sl) * 2013-07-31 2018-10-30 Farma Grs, D.O.O. Proces za pripravo tulatromicina
CN103497227B (zh) * 2013-09-13 2015-09-30 青岛科技大学 一种泰拉菌素中间体的制备方法
CN104725446B (zh) * 2015-03-26 2017-10-27 宁夏泰瑞制药股份有限公司 一种从泰拉霉素粗品中分离泰拉霉素a和泰拉霉素b的方法
CN104861018A (zh) * 2015-06-17 2015-08-26 瑞普(天津)生物药业有限公司 一种泰拉菌素的制备方法
CN105646617A (zh) * 2016-01-21 2016-06-08 杭州海尔希畜牧科技有限公司 一种制备泰拉霉素的方法
FR3048612B1 (fr) * 2016-03-14 2020-10-02 Septeos Tulathromycine potentialisee
CN106046077B (zh) * 2016-08-04 2019-07-26 湖北美天生物科技股份有限公司 一种泰拉霉素a的合成方法
CN108003207B (zh) 2017-12-19 2019-05-10 海门慧聚药业有限公司 制备泰拉霉素的方法
CN111087433B (zh) * 2018-10-23 2023-03-21 湖北美天生物科技股份有限公司 一种泰拉霉素中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
CA2064634C (en) * 1991-04-04 1998-08-04 James V. Heck 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions
US5226958A (en) * 1991-04-11 1993-07-13 Pacemark, Inc. Sealant for pneumatic inner tubes and tubeless tires
EP0549040A1 (en) 1991-12-20 1993-06-30 Merck & Co. Inc. Methods of making 4" derivatives of 9-deoxo-8a-aza-8a-alkyl-8a-homoerythromycin A
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
UA70972C2 (uk) 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків

Also Published As

Publication number Publication date
HK1088014A1 (zh) 2006-10-27
EP0988310B9 (en) 2006-03-08
HRP980314B1 (en) 2004-04-30
NZ500660A (en) 2002-03-01
UA67744C2 (uk) 2004-07-15
JP3315704B2 (ja) 2002-08-19
OA11224A (en) 2003-07-16
RS49675B (sr) 2007-11-15
AP9801255A0 (en) 1998-06-30
HUS1200028I1 (hu) 2016-08-29
EA199901015A1 (ru) 2000-06-26
NO316911B1 (no) 2004-06-21
US20040023896A1 (en) 2004-02-05
KR20010013632A (ko) 2001-02-26
SK284171B6 (sk) 2004-10-05
TW472060B (en) 2002-01-11
NL300150I2 (nl) 2004-09-01
AU749816B2 (en) 2002-07-04
CO4950611A1 (es) 2000-09-01
CA2293823A1 (en) 1998-12-17
HUP0002209A3 (en) 2003-05-28
BG64391B1 (bg) 2004-12-30
IS1998B (is) 2005-03-15
NO996106L (no) 2000-02-10
BRPI9810519B8 (pt) 2022-11-16
ES2205487T3 (es) 2004-05-01
GT199800077A (es) 1999-12-02
HUP0002209A2 (hu) 2000-12-28
JP2000514098A (ja) 2000-10-24
SK284171B9 (sk) 2005-03-04
SK168399A3 (en) 2000-11-07
HRP980314A2 (en) 1999-04-30
WO1998056802A1 (en) 1998-12-17
LU91076I2 (fr) 2004-07-05
US20020061858A1 (en) 2002-05-23
MA24564A1 (fr) 1998-12-31
PL191601B1 (pl) 2006-06-30
NZ514871A (en) 2003-08-29
DK0988310T3 (da) 2003-12-15
AP1231A (en) 2003-12-11
NL300150I1 (nl) 2004-08-02
BRPI9810519A (pt) 2000-09-19
YU58699A (pt) 2002-08-12
ATE251173T1 (de) 2003-10-15
CN101691390A (zh) 2010-04-07
PA8452201A1 (es) 2000-05-24
EP0988310B1 (en) 2003-10-01
US6936592B2 (en) 2005-08-30
CN1793155A (zh) 2006-06-28
CA2293823C (en) 2004-02-17
PT988310E (pt) 2003-12-31
AU7347598A (en) 1998-12-30
IL132809A0 (en) 2001-03-19
CN1566129A (zh) 2005-01-19
EG24081A (en) 2008-05-11
BG103945A (bg) 2000-07-31
CN1172947C (zh) 2004-10-27
JP2002316933A (ja) 2002-10-31
IS5252A (is) 1999-11-16
CN1259136A (zh) 2000-07-05
UY25040A1 (es) 2000-09-29
SI0988310T1 (en) 2004-02-29
FR04C0013I2 (pt) 2005-10-21
HK1068893A1 (en) 2005-07-29
LU91076I9 (en) 2018-07-02
DE122004000018I2 (de) 2011-01-13
US6420536B1 (en) 2002-07-16
TNSN98082A1 (fr) 2005-03-15
EP0988310A1 (en) 2000-03-29
PE79699A1 (es) 1999-08-25
US6777393B2 (en) 2004-08-17
DZ2514A1 (fr) 2003-02-01
AR013086A1 (es) 2000-12-13
KR100396168B1 (ko) 2003-08-27
CZ298556B6 (cs) 2007-11-07
ME00876B (me) 2012-06-20
DE122004000018I1 (de) 2004-09-30
ZA985017B (en) 1999-12-17
CZ442199A3 (cs) 2000-07-12
DE69818665D1 (de) 2003-11-06
DE69818665T2 (de) 2004-04-29
US20040180842A1 (en) 2004-09-16
NO996106D0 (no) 1999-12-10
HU228005B1 (en) 2012-08-28
CN1243766C (zh) 2006-03-01
EA002441B1 (ru) 2002-04-25
FR04C0013I1 (pt) 2004-06-11
PL337505A1 (en) 2000-08-28
HN1998000086A (es) 1999-03-08
MY123354A (en) 2006-05-31
HK1028048A1 (en) 2001-02-02
ID22992A (id) 1999-12-23
CN1793155B (zh) 2010-05-12

Similar Documents

Publication Publication Date Title
ATE187063T1 (de) Arzneimittel
ID24654A (id) Formulasi farmasi omeprazola
NL300295I1 (nl) 3,3-Diarylpropylaminen, de toepassing en bereiding hiervan
ID20053A (id) Hipolipidemat 1,4-benzotiazepin-1,1-dioksida
HUS1200028I1 (hu) 4"-Szubsztituált-9-dezoxo-9a-aza-9a-homoeritromicin-származékok és ezeket tartalmazó gyógyszerek
IS5425A (is) Læknislyf
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
DE69737936D1 (de) Arzneimittel
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
NO980546D0 (no) Farmasöytiske midler
TR199800988A3 (tr) 5' Deoksi-Sitidin türevleri.
EE9900545A (et) Farmatseutiline kompositsioon
BR9811582B1 (pt) compostos derivados de 4-oxo-3,5-di-hidro-4h-piridazino[4,5-b]indol-1-acetamid a, medicamento e composição farmacêutica contendo os mesmos.
BR9507768A (pt) Composição farmacêutica
ID29294A (id) Komposisi farmasi
TR199501082A2 (tr) Farmasötik formülasyonlar.
FI973229L (fi) Uusi farmaseuttinen koostumus
ID25857A (id) Komposisi farmasi
FI961364L (fi) Lääkeainekoostumus
MA26481A1 (fr) Derives d'arylsecocholadiene
NO306672B1 (no) N,N-dietyl-8,8-dipropyl-2-azaspiro[4,5]decan-2-propanamindimaleat, farmasöytisk blanding omfattende forbindelsen samt anvendelse derav
ID23531A (id) Komposisi farmasi
BR1100929A (pt) Derivados 1,2-difenilpirrol e uma composição farmacêutica
BR1100391A (pt) Composto e composição farmacêutica

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25D Requested change of name of applicant approved
B25C Requirement related to requested transfer of rights

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 860150304618 DE 23/12/2015, E NECESSARIO E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO DE CESSAO, CONFORME ART. 18 DO DEC. 13.609/43.

B25A Requested transfer of rights approved
B25G Requested change of headquarter approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/98, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2635 DE 06/07/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2146, DE 22/02/2012. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22.02.2022

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2146, DE 22/02/2012. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS, PARA MATERIA RELATIVA A PRODUTOS E PROCESSOS COM APLICACAO VETERINARIA. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.